Logo image of FSTX

F-STAR THERAPEUTICS INC (FSTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FSTX - US30315R1077 - Common Stock

7.12 USD
0 (0%)
Last: 3/8/2023, 8:00:00 PM
7.12 USD
0 (0%)
After Hours: 3/8/2023, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FSTX. FSTX was compared to 530 industry peers in the Biotechnology industry. FSTX has a bad profitability rating. Also its financial health evaluation is rather negative. FSTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FSTX has reported negative net income.
FSTX had a negative operating cash flow in the past year.
FSTX Yearly Net Income VS EBIT VS OCF VS FCFFSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

FSTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FSTX Yearly ROA, ROE, ROICFSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

FSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FSTX Yearly Profit, Operating, Gross MarginsFSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -1K -2K -3K -4K -5K

More info and screens

3

2. Health

2.1 Basic Checks

FSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FSTX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FSTX is higher compared to a year ago.
FSTX Yearly Shares OutstandingFSTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
FSTX Yearly Total Debt VS Total AssetsFSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.67, we must say that FSTX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.67, FSTX is doing good in the industry, outperforming 61.16% of the companies in the same industry.
A Debt/Equity ratio of 0.15 indicates that FSTX is not too dependend on debt financing.
FSTX has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: FSTX underperforms 65.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC8.16%
FSTX Yearly LT Debt VS Equity VS FCFFSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.
The Current ratio of FSTX (3.38) is worse than 67.45% of its industry peers.
A Quick Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.38, FSTX is not doing good in the industry: 66.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
FSTX Yearly Current Assets VS Current LiabilitesFSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.57% over the past year.
FSTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.64%.
The Revenue has been growing by 127.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%

3.2 Future

The Earnings Per Share is expected to grow by 5.63% on average over the next years.
The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FSTX Yearly Revenue VS EstimatesFSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
FSTX Yearly EPS VS EstimatesFSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FSTX. In the last year negative earnings were reported.
Also next year FSTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FSTX Price Earnings VS Forward Price EarningsFSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FSTX Per share dataFSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as FSTX's earnings are expected to decrease with -11.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%

More info and screens

0

5. Dividend

5.1 Amount

FSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

F-STAR THERAPEUTICS INC

NASDAQ:FSTX (3/8/2023, 8:00:00 PM)

After market: 7.12 0 (0%)

7.12

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2023-03-13
Earnings (Next)05-08 2023-05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap156.51M
Revenue(TTM)21.18M
Net Income(TTM)-44.75M
Analysts48.89
Price Target7.14 (0.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.03%
Min EPS beat(2)-47.48%
Max EPS beat(2)-4.58%
EPS beat(4)2
Avg EPS beat(4)120.51%
Min EPS beat(4)-47.48%
Max EPS beat(4)516.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1738.24%
Min Revenue beat(2)-100%
Max Revenue beat(2)3576.47%
Revenue beat(4)3
Avg Revenue beat(4)910.2%
Min Revenue beat(4)-100%
Max Revenue beat(4)3576.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.39
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 5.88
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.96
BVpS2.59
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 0.67
F-Score2
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)80.51%
Cap/Depr(5y)224.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%
EBIT growth 1Y25.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.25%
EBIT Next 3Y-23.59%
EBIT Next 5Y-14.31%
FCF growth 1Y-57.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.9%
OCF growth 3YN/A
OCF growth 5YN/A

F-STAR THERAPEUTICS INC / FSTX FAQ

What is the fundamental rating for FSTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to FSTX.


What is the valuation status for FSTX stock?

ChartMill assigns a valuation rating of 1 / 10 to F-STAR THERAPEUTICS INC (FSTX). This can be considered as Overvalued.


How profitable is F-STAR THERAPEUTICS INC (FSTX) stock?

F-STAR THERAPEUTICS INC (FSTX) has a profitability rating of 0 / 10.


What is the financial health of F-STAR THERAPEUTICS INC (FSTX) stock?

The financial health rating of F-STAR THERAPEUTICS INC (FSTX) is 4 / 10.


What is the earnings growth outlook for F-STAR THERAPEUTICS INC?

The Earnings per Share (EPS) of F-STAR THERAPEUTICS INC (FSTX) is expected to decline by -39.55% in the next year.